OmniAb (NASDAQ:OABI) is set to give its latest quarterly earnings report on Wednesday, 2026-03-04. Here's what investors need to know before the announcement.

Analysts estimate that OmniAb will report an earnings per share (EPS) of $-0.08.

OmniAb bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings Track Record

In the previous earnings release, the company missed EPS by $0.00, leading to a 3.72% drop in the share price the following trading session.

Here's a look at OmniAb's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.14	-0.15	-0.17	-0.10
EPS Actual	-0.14	-0.15	-0.17	-0.12
Price Change %	-3.72	-2.59	-8.28	-20.38

Tracking OmniAb's Stock Performance

Shares of OmniAb were trading at $1.76 as of March 02. Over the last 52-week period, shares are down 48.83%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

Delving into OmniAb's Background

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Financial Milestones: OmniAb's Journey

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Challenges: OmniAb's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -46.33%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: OmniAb's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -738.05%, the company may face hurdles in effective cost management.

Return on Equity (ROE): OmniAb's ROE stands out, surpassing industry averages. With an impressive ROE of -6.13%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): OmniAb's ROA excels beyond industry benchmarks, reaching -5.46%. This signifies efficient management of assets and strong financial health.

Debt Management: OmniAb's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.

To track all earnings releases for OmniAb visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.